Arena Pharma (ARNA) Tops Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers
August 5, 2021 7:00 AM EDTBRISBANE, Calif., Aug. 5, 2021 /PRNewswire/ --Â Second Genome, a biotechnology company that leverages its proprietary platform sg-4-sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced they are entering a strategic collaboration with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod.Â
Under the terms of the agreement, Second Genome will utilize its proprietary sg-4-sight discovery engine to identify microbiome biomarkers associated with clinical benefit or adverse effects observed... More
